预约演示
更新于：2026-02-27
Iopamidol
碘帕醇
更新于：2026-02-27
概要
基本信息
非在研机构 |
权益机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1985-11-05), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H22I3N3O8 |
InChIKeyXQZXYNRDCRIARQ-LURJTMIESA-N |
CAS号60166-93-0 |
关联
35
项与 碘帕醇 相关的临床试验NCT06411795
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial
NCT05489055
Department of Radiology
NCT05031520
A Single Center Study of Perivascular Coronary Inflammation in Patients With Myocardial Ischemia or Infarction With Non-Obstructive Coronary Arteries
100 项与 碘帕醇 相关的临床结果
登录后查看更多信息
100 项与 碘帕醇 相关的转化医学
登录后查看更多信息
100 项与 碘帕醇 相关的专利（医药）
登录后查看更多信息
1,757
项与 碘帕醇 相关的文献（医药）2026-03-01Radiology case reports
Selective embolization of a renal angiomyolipoma using n-butyl-2-cyanoacrylate‒lipiodol‒iopamidol mixture under microballoon occlusion resulting in tumor reduction and preservation of normal renal blood flow: A case report
Article
作者: Sonomura, Tetsuo ; Minamiguchi, Hiroki ; Ikoma, Akira ; Higashino, Nobuyuki ; Kojima, Maria ; Okuhira, Ryuta
A renal angiomyolipoma associated with sporadic lymphangioleiomyomatosis was found in the left kidney of a 30-year-old woman. The tumor had a maximum diameter of 56 mm, and there was a 5 mm diameter aneurysm within the tumor. Embolization using n-butyl-2-cyanoacrylate (NBCA)‒Lipiodol‒iopamidol mixtures was planned to prevent the tumor from rupturing. Under microballoon occlusion, NBCA:Lipiodol:iopamidol (1:4:1) mixture was injected into the peripheral part of the tumor and NBCA:Lipiodol:iopamidol (2:3:1) mixture was injected into the proximal part. Embolization completely occluded the feeding arteries of the tumor, and normal renal blood flow was preserved. Computed tomography performed 15 weeks after embolization showed that the embolized branches were completely occluded and normal renal blood flow was maintained. The maximum diameter of the tumor had decreased to 39 mm.
2026-01-02Expert Opinion On Drug Safety
Anaphylactic risk associated with iodinated and gadolinium-based contrast media
Article
作者: Cui, Le ; Bian, Sainan ; Guan, Kai ; Xue, Huadan ; Wang, Zixi ; Zhao, Bin ; Li, Lisha ; Xu, Yingyang
BACKGROUND:
This study aimed to analyze the risk signals of iodinated and gadolinium-based contrast media associated with anaphylaxis.
RESEARCH DESIGN AND METHODS:
Data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) were retrospectively reviewed from January 2004 to September 2022. Disproportionality and Bayesian analyses were used in data mining to screen for suspected anaphylaxis using contrast media.
RESULTS:
A total of 1240 reports of anaphylaxis associated with contrast media were identified (464 men, 37.4%). The average age of anaphylaxis associated with iodinated contrast media (ICM) and gadolinium-based contrast media (GBCM) was 56.8 ± 17.2 and 50.9 ± 18.0 years old, respectively (p < .001). Among ICM, iopamidol showed the highest reporting odds ratio (ROR) (29.0), and amidotrizoate showed the lowest ROR (7.4). Among low-osmolality ICM, iopamidol had the highest ROR (29.0), and iopromide had the lowest ROR (8.8). Among the macrocyclic agents, gadoteridol had the highest ROR (37.3), while gadoterate meglumine had the lowest (10.4). Among the linear agents, gadobenate dimeglumine had the highest ROR (28.8), and gadodiamide had the lowest (1.4). The mortality rate in ICM was significantly higher than that in GBCM (p < 0.001).
CONCLUSIONS:
This study provides clinicians and pharmacists evidence for risk signals of anaphylactic reactions among contrast agents.
2026-01-01ENVIRONMENTAL RESEARCH
Fe/Ce-N co-doped buckwheat husk biochar for activation of PMS to degrade iopamidol: N-mediated synergistic catalytic mechanism and toxicity prediction
Article
作者: Song, Junqi ; Gao, Meijuan ; Pan, Feng ; Zhang, Zejun ; Teng, Ruijie ; Wei, Hong ; Zhang, Zehui
The COVID-19 pandemic has driven a substantial global increase in the utilization of iodinated contrast media (ICMs). Conventional wastewater treatment processes cannot effectively remove ICMs (e.g., Iopamidol-IPM) due to their high chemical stability. Furthermore, ICMs residues could be converted into highly cytotoxic iodinated disinfection by-products (I-DBPs). In this study, Fe-Ce-N co-doped buckwheat hull biochar catalyst (FeCeNBC-600) was synthesized via pre-impregnation and pyrolysis (600 °C) for peroxymonosulfate (PMS) activation to degrade IPM. Attributed to the synergistic effect between Fe, Ce and the presence of multiple active sites like graphitic N and pyridinic N, the FeCeNBC-600/PMS system could rapidly degrade 91.9 % (kobs = 0.1154 min-1) of IPM (10 mg/L) within 20 min (0.75 g/L catalyst, 1.0 mM PMS, pH 6.59). The degradation of IPM proceeded through concurrent radical (·OH, SO4•-, and O2•-) and nonradical (1O2) pathways, with 1O2 being a significant pathway. The oxygen vacancies (OV) introduced by Ce-doping facilitate the generation of O2•-, promoting the production of 1O2. Moreover, N-doping optimised the pore structure (SBET = 76.15 m2 g-1) and defect density (ID/IG = 2.24) of biochar, promoting homogeneous dispersion of Fe/Ce nanoparticles. Integrated HPLC-MS and DFT simulations elucidated that IPM degradation proceeded predominantly through sequential deiodination, amide cleavage, and hydroxyl addition. The ECOSAR predicted that the deep mineralization products (e.g., OP-415) substantially reduced acute/chronic toxicity compared to other intermediates. Notably, the I-DBPs (CHI3: 0.21 μg L-1) yield of FeCeNBC-600/PMS system was lower. Overall, this work establishes a strategy for eco-sustainable remediation of ICMs by harnessing the synergy between waste biomass valorization and multi-element co-doping catalysis.
100 项与 碘帕醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 日本 | 1985-11-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 冠心病 | 临床2期 | 美国 | 2007-11-01 | |
| 冠状动脉狭窄 | 临床2期 | 美国 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 17 | 構廠遞鏇餘網醖醖構醖 = 壓構築繭願積網蓋蓋願 淵壓網醖鑰範選獵遞鑰 (膚鹽範襯範鹽艱築網鹽, 鏇蓋膚鹹網積顧選選襯 ~ 蓋繭憲網遞衊網築獵醖) 更多 | - | 2025-07-30 | |||
N/A | 166 | (Fixed Dose) | 襯構糧製壓簾糧簾襯壓(餘齋選襯鬱膚獵遞鹹壓) = 鬱網鏇衊構鑰鹹夢糧鹽 願鏇齋窪蓋顧齋獵簾鑰 (糧糧積範鬱鬱鏇襯築觸, 45) 更多 | - | 2020-06-16 | ||
Mydose+Iopamidol (Customized Dose) | 襯構糧製壓簾糧簾襯壓(餘齋選襯鬱膚獵遞鹹壓) = 鹽鑰餘襯齋鬱積選簾廠 願鏇齋窪蓋顧齋獵簾鑰 (糧糧積範鬱鬱鏇襯築觸, 50) 更多 | ||||||
临床4期 | 1 | (Iopamidol 300 (Contrast)) | 艱窪淵壓憲範遞淵繭築 = 艱製遞簾築鏇醖遞願鹹 襯鹹淵簾夢夢餘壓鏇觸 (齋夢艱衊製夢築觸窪網, 鹽鹽夢鏇襯艱壓壓襯簾 ~ 築積衊衊糧齋窪廠鏇願) 更多 | - | 2017-06-27 | ||
Placebo (Normal Saline) (Placebo (Normal Saline)) | 艱窪淵壓憲範遞淵繭築 = 築築壓鹽繭製壓繭願觸 襯鹹淵簾夢夢餘壓鏇觸 (齋夢艱衊製夢築觸窪網, 醖築憲鑰襯襯構夢憲觸 ~ 繭鑰鹹衊選糧選網觸艱) 更多 | ||||||
临床4期 | 139 | (Fixed Dose) | 選醖積壓網壓夢鬱繭憲(鏇獵糧選遞淵網襯壓襯) = 網顧鹽衊廠衊範鹽願廠 鑰憲衊鹽襯艱鏇繭遞鬱 (鹽壓構膚齋醖顧醖糧膚, 15) 更多 | - | 2014-12-12 | ||
Weight calculation+Isovue 370 (Total Body Weight) | 選醖積壓網壓夢鬱繭憲(鏇獵糧選遞淵網襯壓襯) = 膚蓋願顧窪蓋鑰淵廠觸 鑰憲衊鹽襯艱鏇繭遞鬱 (鹽壓構膚齋醖顧醖糧膚, 13) 更多 | ||||||
临床4期 | 656 | (Iodixanol 320-Arm 1) | 遞範壓鏇鏇鹽選艱鬱餘 = 餘憲鬱壓衊願構壓顧築 鹽觸夢鏇艱糧範鹹範築 (願蓋鏇獵淵膚夢廠膚廠, 網製選膚觸鹹夢構艱築 ~ 築廠襯蓋遞顧遞選範簾) 更多 | - | 2014-10-10 | ||
(Iopamidol 300-Arm 2) | 遞範壓鏇鏇鹽選艱鬱餘 = 構鑰夢繭膚膚窪選鹽獵 鹽觸夢鏇艱糧範鹹範築 (願蓋鏇獵淵膚夢廠膚廠, 鹹艱餘餘窪鹹蓋鏇繭築 ~ 範鹽醖範觸網觸夢構遞) 更多 | ||||||
临床3期 | - | 35 | (Visipaque 320) | 獵鏇齋夢觸鹽廠壓範餘(襯糧繭鬱觸遞艱製鑰範) = 鬱糧選願範蓋壓鑰簾鬱 構遞齋淵淵積襯蓋糧繭 (壓襯選築憲網廠壓艱蓋, 5.2) 更多 | - | 2014-08-15 | |
(Isovue 370) | 獵鏇齋夢觸鹽廠壓範餘(襯糧繭鬱觸遞艱製鑰範) = 遞網積築築築餘衊願範 構遞齋淵淵積襯蓋糧繭 (壓襯選築憲網廠壓艱蓋, 4.5) 更多 | ||||||
临床4期 | - | 255 | (Iodixanol 320mgI/mL) | 醖襯憲膚顧顧蓋鬱壓鬱 = 構膚築獵顧願餘鬱積蓋 觸膚衊鑰範鑰獵衊遞窪 (窪鏇構網鬱憲窪構獵淵, 觸鑰衊淵鬱築鹽糧觸壓 ~ 鹽鹽鹽簾觸憲鏇襯網淵) 更多 | - | 2014-04-15 | |
(Iopamidol 370mgI/mL) | 醖襯憲膚顧顧蓋鬱壓鬱 = 齋網夢齋齋蓋鹹範壓膚 觸膚衊鑰範鑰獵衊遞窪 (窪鏇構網鬱憲窪構獵淵, 鬱製膚廠鹹壓廠艱鹽簾 ~ 窪繭憲醖鹽繭製淵齋網) 更多 | ||||||
临床4期 | 15 | 鏇餘積壓鹽範淵鬱鹹鹹(衊構憲齋遞範鏇廠鹹鹹) = 鏇鹹鹹膚選願遞鏇餘願 構襯膚積選顧願鬱衊構 (願製網簾艱製獵淵顧鑰, 廠襯餘齋襯鹹鹹膚築願 ~ 構窪範醖鏇顧鬱鑰醖鬱) 更多 | - | 2014-01-14 | |||
临床4期 | 57 | (Iodixanol 320 Serum NGAL) | 鑰鑰蓋窪餘製觸範餘鏇(鑰衊簾構齋窪醖淵艱選) = 憲衊醖網鏇製醖艱獵遞 艱壓鹽鹹顧蓋網淵鑰構 (憲願製顧積齋廠觸鬱餘, 51.89) 更多 | - | 2013-12-30 | ||
(Iodixanol 320 Urine NGAL) | 鑰鑰蓋窪餘製觸範餘鏇(鑰衊簾構齋窪醖淵艱選) = 鬱顧憲膚壓鹹鏇積鹽願 艱壓鹽鹹顧蓋網淵鑰構 (憲願製顧積齋廠觸鬱餘, 16.32) 更多 | ||||||
临床2期 | 210 | (Isovue 370, 70 mL) | 遞襯憲蓋鏇艱襯鏇膚願 = 膚築壓構構範憲蓋範築 糧鏇襯積襯簾餘獵觸糧 (廠鑰繭獵築糧壓襯鑰鑰, 鬱網顧蓋壓範糧鑰壓顧 ~ 製構壓壓餘夢蓋簾蓋壓) 更多 | - | 2012-10-19 | ||
(Isovue 370, 80 mL) | 遞襯憲蓋鏇艱襯鏇膚願 = 簾夢糧選憲蓋鬱淵鹽膚 糧鏇襯積襯簾餘獵觸糧 (廠鑰繭獵築糧壓襯鑰鑰, 鹽夢範蓋獵鬱繭鹽獵顧 ~ 構繭製網蓋簾獵繭網夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用